OR-003

OR-003 is a preclinical-stage therapeutic candidate being developed by OccamzRazor for the treatment of Parkinson's disease. Identified through the company's machine learning platform, OR-003 is designed to address the complex multifactorial nature of neurodegeneration by targeting several key biological pathways, including chromatin remodeling, mitochondrial health, lysosomal function, and oxidative stress. The drug specifically aims to prevent the death of dopaminergic (DA) neurons and modulate sphingolipid metabolism and growth factor signaling. It is positioned to target specific patient subgroups defined by clinical phenotypes such as age of onset and medical history.